SaNOtize, a Canada-based pharmaceutical firm has claimed that its nitric oxide nasal spray can be used as an effective treatment for Covid-19 as it kills 99.9 percent of the virus. The company has even sought emergency approval from the United Kingdom and Canada for the use of its nasal spray.
Evaluating 79 confirmed cases of covid 19 with the United Kingdom variant, the randomized, double-blind, placebo-controlled Phase 2 trial indicated that SaNOtize reduces the level of SARS-CoV-2 in the patients within the first 24 hours by 95%. In 72 hours, it reduced the viral load by 99%. There were no adverse health events recorded in the UK trial, or in over 7,000 self-administered treatments given in earlier Canadian clinical trials.
“I expect this to be a major advance in the global battle against the devastating human impacts of the Covid-19 pandemic,” said consultant medical virologist and chief investigator of the NHS trial Dr Stephen Winchester.
Chris Miller, PhD, RT, chief science officer and co-founder of SaNOtize, in a press release mentioned that NONS destroys the virus, blocks entry into and halts viral replication within the nasal cavity, which rapidly reduces viral load.
“There is currently a lack of an antiviral therapy that is effective against COVID-19 and its variants, can prevent or shorten the course of the disease, reduce damage, lower the severity of COVID-19, and can be made widely and readily available to the public,” he added further.
Israel and New Zealand have already approved the public sale of NONS. It will be sold under the brand name of Enovid in Israel and is expected to hit the shelves this summer.